Alitair Pharmaceuticals Announces Issuance Of An Additional Patent Covering Its Platform Drug Delivery Technology, REA™
MORRISTOWN, N.J.--(BUSINESS WIRE)--Alitair Pharmaceuticals, Inc., a revenue-stage pharmaceutical company with multiple respiratory product candidates in development, today announced the issuance of U.S. Patent No. 8,617,602 from the United States Patent and Trademark Office (USPTO) for its ion exchange resin drug delivery technology, REA™.
Help employers find you! Check out all the jobs and post your resume.